Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor...
-
Upload
vernon-knight -
Category
Documents
-
view
215 -
download
0
Transcript of Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor...
![Page 1: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/1.jpg)
Screening and Treatment of Screening and Treatment of Coronary Artery DiseaseCoronary Artery Disease
Matthew J. Budoff, MD, FACCMatthew J. Budoff, MD, FACC
Associate Professor of MedicineAssociate Professor of Medicine
Division of Cardiology, Division of Cardiology,
Harbor-UCLA Medical Center, Torrance, CADISCLOSURE INFORMATION:The following relationships exist related to this presentation:
![Page 2: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/2.jpg)
Electron Beam Computerized Tomography
Crystal-photodiodes
Preamplifiers
Sourcecollimator
Target ring
Vacuum envelope
Patient crosssection
47cm scanfield
Target rings
Sourcecollimator
Radiationshield
Vacuumchamber
Heart
Detectors
![Page 3: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/3.jpg)
Coronary Artery Scanning
NORMAL CONDITION
![Page 4: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/4.jpg)
Coronary Artery Scanning
SEVERECALCIFICATION
![Page 5: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/5.jpg)
CAC vs HISTOLOGYCAC vs HISTOLOGY
High correlation of score (r=0.96) and area (r=0.95) with histomorphometry (p<0.0001)
“.. the amount of coronary calcium increases as the extent of atherosclerosis increases”
Mautner GC et al: Radiology 1994;192:619-623
![Page 6: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/6.jpg)
20%20%
80%80%
Total Coronary Artery PlaqueTotal Coronary Artery Plaqueand EBCT Coronary Calciumand EBCT Coronary Calcium
80%80%
PlaquePlaqueDetectableDetectableby IVUS,by IVUS,PathologyPathology
Lipid RichLipid Rich
FibroticFibrotic
CalcifiedCalcified 20%20%
80%80%
![Page 7: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/7.jpg)
Calcium ScoreCalcium Score
Total PlaqueTotal PlaqueBurdenBurden
Total Coronary Artery Plaque Burden andTotal Coronary Artery Plaque Burden andEBCT Coronary Calcium Score:EBCT Coronary Calcium Score:
defining the tip of the atherosclerotic icebergdefining the tip of the atherosclerotic iceberg
Mild Plaque SevereModerate
![Page 8: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/8.jpg)
Framingham Risk in the Young
222 patients with AMI (men < 55, women <65)
Only 25% qualified for pharmacotherapy based on 10-year risk prior to MI
Only 18% of women met criteria
Akosah – JACC 2003
![Page 9: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/9.jpg)
Prediction of Cardiac Events in AsymptomaticPrediction of Cardiac Events in AsymptomaticPatients by EBTPatients by EBT
Pohle, Heart 2003:89:625-628Pohle, Heart 2003:89:625-628
102 patients with AMI, age < 60 years 95.1% had calcification present Only 5.8% of controls had calcification present
(p<0.0001) Agatston >50% score – present in 87% By extrapolation, this test may allow identification of
87-95% of the 650,000 patients whose first presentation is Myocardial infarction or cardiac death
![Page 10: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/10.jpg)
Refining Framingham Risk ScoreRefining Framingham Risk Score
EBT derived “Arterial Age”
a man is as old as his coronaries…
Syndenham 1689
EBT derived “Arterial Age”
a man is as old as his coronaries…
Syndenham 1689
![Page 11: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/11.jpg)
EBCT CORONARY CALCIUM SCORES AS FUNCTION OF AGE AND GENDER
MALES
0100200300400500600700800900
1000
30-39 40-49 50-59 60-69 70+
10th25th50th75th90th
![Page 12: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/12.jpg)
EBCT CORONARY CALCIUM SCORES AS FUNCTION OF AGE AND GENDER
FEMALES
0
100
200
300
400
500
600
700
800
900
30-39 40-49 50-59 60-69 70+
10th25th50th75th90th
A
![Page 13: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/13.jpg)
Negative Predictive Power of EBT
1764 persons underwent EBT and angiogram Sensitivity for Obstruction (any calcium)
99.4% in men, 100% in women Negative predictive power > 99% Can be used as a ‘filter’ prior to angiography
to help avoid negative angiograms
Haberl et al. JACC Feb 2001
![Page 14: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/14.jpg)
EBCT “Screening” in the Emergency Room:EBCT “Screening” in the Emergency Room:Results in the Mayo Clinic “chest pain unit”Results in the Mayo Clinic “chest pain unit”
EBCT ResultsPositive Negative Total
Other Cardiac Test Results (Score > 0) (Score = 0)
Positive Dx of CAD 14 0 14Negative Dx of CAD 32 54 86
Total
EBCT Results:
SensitivitySpecificity
Negative Predictive Value
46
100%63%
100%
54 100
NPV for “Significant”CAD of 100%
50% women, 98% Caucasian
All events occurred in those with CAC
Annals of Em Med, 1999
![Page 15: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/15.jpg)
CARDIOMYOPATHYCARDIOMYOPATHY Evaluate Cardiomyopathy of Unknown Etiology
using EBT
The sensitivity of coronary calcium depicting an ischemic cardiomyopathy was 99% (score >0 = presumed ischemic CM) 1
Better than echocardiography or stress testing at distinguishing ischemic from dilated CM2
1Budoff et al. JACC 1999
2Le T. Clin Card 2000
![Page 16: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/16.jpg)
Sensitivity of Calcium for Future Cardiovascular Events
0%
10%
20%
30%
40%
50%60%
70%
80%
90%
100%
RiskFactors
Detrano Greenland Raggi Arad Wong Agatston Detrano Georgio Keelan
![Page 17: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/17.jpg)
Rusty Pipe Model of Atherosclerosis
![Page 18: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/18.jpg)
NormalNormalvesselvessel
MinimalMinimalCADCAD
ProgressionProgression
Artery can compensate for up Artery can compensate for up to 40% plaque volume (lumen to 40% plaque volume (lumen
size remains constant)size remains constant)
Artery atArtery atmaximummaximumexpansion:expansion:
lumen narrowslumen narrows
SevereSevereCADCAD
ModerateModerateCADCAD
Glagov S et al, Glagov S et al, N Engl J MedN Engl J Med, 1987., 1987.
Glagov Hypothesis: Coronary Remodeling
Glagov Hypothesis: Coronary Remodeling
![Page 19: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/19.jpg)
NormalNormalvesselvessel
MinimalMinimalCADCAD
ProgressionProgression
Artery can compensate for up Artery can compensate for up to 40% plaque volume (lumen to 40% plaque volume (lumen
size remains constant)size remains constant)
Artery atArtery atmaximummaximumexpansion:expansion:
lumen narrowslumen narrows
SevereSevereCADCAD
ModerateModerateCADCAD
Glagov S et al, Glagov S et al, N Engl J MedN Engl J Med, 1987., 1987.
Glagov Hypothesis: Coronary Remodeling
Glagov Hypothesis: Coronary Remodeling
![Page 20: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/20.jpg)
NormalNormalvesselvessel
MinimalMinimalCADCAD
ProgressionProgression
Artery can compensate for up Artery can compensate for up to 40% plaque volume (lumen to 40% plaque volume (lumen
size remains constant)size remains constant)
Artery atArtery atmaximummaximumexpansion:expansion:
lumen narrowslumen narrows
SevereSevereCADCAD
ModerateModerateCADCAD
Glagov S et al, Glagov S et al, N Engl J MedN Engl J Med, 1987., 1987.
Glagov Hypothesis: Coronary Remodeling
Glagov Hypothesis: Coronary Remodeling
![Page 21: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/21.jpg)
False Negative Coronary Angiography
Diffuse Atherosclerosis despite negative angiogram
Images supplied by Steven E. Nissen, MD, Cleveland Clinic.
![Page 22: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/22.jpg)
Asymptomatic PersonsAsymptomatic Persons Nuclear Imaging Nuclear Imaging
0 0 2.6
11.3
46
0 03.1
6.6
40.4
0
10
20
30
40
50
Zero 1 10 11-100 101-400 400-1000
Total Calcium Score
Per
cent
age
Pos
itiv
e
Pos MIBI Cath
Hu, Circulation 2000
![Page 23: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/23.jpg)
Historical Development of a Coronary Artery Plaque
This process, in various stages of development, can be seen in manyareas of the coronary artery system, consistent with the “diffuse” natureof coronary artery disease
EBCT “positive” for coronary calcium
![Page 24: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/24.jpg)
![Page 25: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/25.jpg)
DATA TAKEN FROM “THE DAWN OF A NEW ERA -NON-INVASIVE CORONARY IMAGING” R. ERBEL HERZ 1996; 21, 75-77
DIAGNOSTIC SENSITIVITY
0% 20% 45% 60% 70% 90%
INVASIVEMODALITIES
STRESS ECG $300
STRESS ECHO $900
PET SCANNING $2200
ELECTRON BEAM CT $400
NON-INVASIVE MODALITIES
INTRAVASCULAR ULTRASOUND $3,000
CORONARY ANGIOGRAPHY $5,000
STRESS THALLIUM $1600
![Page 26: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/26.jpg)
The challenge in diagnosis of coronary heart disease
““The majority of people destined to die The majority of people destined to die suddenly will not have a positive exercise test. suddenly will not have a positive exercise test. The likely reason that they will die suddenly is The likely reason that they will die suddenly is that only a mild, non-flow -limiting coronary that only a mild, non-flow -limiting coronary plaque will have been present before the plaque will have been present before the sudden development of an occlusive sudden development of an occlusive thrombus.”thrombus.”
- Stephen Epstein - Stephen Epstein New England Medical Journal 1989New England Medical Journal 1989
![Page 27: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/27.jpg)
RR of MI/SCD: EBT Score and hs-CRP
0
1
2
3
4
5
6
7
High CAC Med. CAC Low CACLow hs-CRP
High hs-CRP
Park et al.Circ. 2002;106-2073-2077
![Page 28: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/28.jpg)
0
10
20
30
40
50
60
70
Events in PatientsWith CAC
Events in PatientsWithout CAC
CAC by EBT and Cardiac EventsCAC by EBT and Cardiac Events
n=6499%
n=11%
696 pts.53+11 yrs50% males2.7 year f/u
Raggi et alCirc 2/00
65 Cardiac Events(Cardiac Death,
MI, Revasc)
Event Rate: 6%/yr <.1%/year
![Page 29: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/29.jpg)
Event Rates Based upon Scores
0.8
21
41
480
2040
60
Estimated10 Year Event
Rate
Zero 1 99 100-400 >400
EBT Calcium Score
Raggi, AHJ 2001
![Page 30: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/30.jpg)
Eve
nt F
ree
Sur
viva
l %
0
10
20
30
40
50
60
70
80
90
100
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37
Months
Figure 1. Probability of survival free of events in 98 consecutive asymptomatic subjects with calcium score >1,000 on a screening electron beamtomography scan.
Wayhs R, Zelinger A, Raggi P, J Am Coll. Card., Vol 39: pp 225-230, 2002
High Coronary Artery Calcium Scores Pose anExtremely Elevated Risk for Hard Events
![Page 31: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/31.jpg)
Relative Risk Of Future Cardiac Event using EBT
4.9
21 20
8.8 9.6710.8
13.4
0
5
10
15
20
25
Rel
ativ
e R
isk
Detrano Arad Kondos Georgiou Raggi Wong Detrano
![Page 32: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/32.jpg)
Prediction of Cardiac Events in AsymptomaticPrediction of Cardiac Events in AsymptomaticPatients by EBTPatients by EBT
Kondos et al, Circulation 2003;107:2571-2176Kondos et al, Circulation 2003;107:2571-2176
5635 asymptomatic, low to intermediate risk patients, 375635 asymptomatic, low to intermediate risk patients, 37++12 m f/u12 m f/u
Cardiac events: MI, SCD, revascularization, age 30-76, avg 51Cardiac events: MI, SCD, revascularization, age 30-76, avg 51++9 yrs.9 yrs.
1.01.00.750.75 1.251.25 1.501.50 3.03.0 30.030.0
Age: 1.04-1.07Age: 1.04-1.071.051.05
1.391.39Smoking: 1.04-1.87Smoking: 1.04-1.87
0.870.87Elevated TC: 0.65-1.07Elevated TC: 0.65-1.07
1.981.98DM: 1.19-3.28DM: 1.19-3.28
1.331.33HTN: 0.98-1.81HTN: 0.98-1.81
10.4610.46Presence of CAC: 3.85-28.4Presence of CAC: 3.85-28.4
RelativeRelativeRiskRisk
![Page 33: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/33.jpg)
Prediction of Cardiac Events in AsymptomaticPrediction of Cardiac Events in AsymptomaticPatients by EBTPatients by EBT
The St. Francis Heart Study, ACC 2003The St. Francis Heart Study, ACC 2003
SFHS 3SFHS 3
0.12
0.7
2
2.4
3.3
0
0.5
1
1.5
2
2.5
3
3.5
0 > 0 > 100 > 200 > 600
Baseline EBT Calcium ScoreBaseline EBT Calcium Score
An
nu
al E
ven
t R
ate
(%)
An
nu
al E
ven
t R
ate
(%)
Calcium Score >100 vs <100
Rel
ativ
e R
isk
9.5
AnyEvent
10.7
Cor.Event
9.9
MI/SCD
![Page 34: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/34.jpg)
![Page 35: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/35.jpg)
![Page 36: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/36.jpg)
2.72 2
12.47
3.55
6.15
12.29
0
2
4
6
8
10
12
14
Rel
ativ
e R
isk
DM Smoke HTN <1010-100
101-400401-1000
>1000
EBT Coronary Calcium ScoreEBT Coronary Calcium Score
All Cause Mortality [NDR]All Cause Mortality [NDR]n = 10,377n = 10,377asymptomatic men and womenasymptomatic men and womenf/u = 5.0f/u = 5.0++3.5 yrs.3.5 yrs.
Shaw, Raggi et alIn Press, Radiology 2003
EBT found to be independentand incremental to risk factors
All Cause Mortality in PatientsAll Cause Mortality in PatientsWithout Known CADWithout Known CAD
![Page 37: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/37.jpg)
5 Year Mortality
![Page 38: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/38.jpg)
EBT 5 year All-Cause Mortality
![Page 39: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/39.jpg)
Risk Stratification – Shaw et al.
![Page 40: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/40.jpg)
Rationale for Use of CAC in Different Populations
Risk
Category
Population Number Shifted
Number Needed to
Scan
Low 35% 2% 50
Intermediate 40% 73% 1.3
High 25% 16% 7
![Page 41: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/41.jpg)
Asymptomatic Patient Algorithm for Asymptomatic Patient Algorithm for Intermediate Risk PatientsIntermediate Risk Patients
Greenland P, et al. Circulation Oct 9, 2001
![Page 42: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/42.jpg)
““measurement of coronary calcium is an option measurement of coronary calcium is an option for advanced risk assessment.for advanced risk assessment.High coronary calcium scores (e.g., >75High coronary calcium scores (e.g., >75 thth percentile for age and sex) denotes advanced percentile for age and sex) denotes advanced atherosclerosis and provides rationale for atherosclerosis and provides rationale for intensified LDL-lowering therapy.”intensified LDL-lowering therapy.”
NCEP ATP-III : Noninvasive TestingNCEP ATP-III : Noninvasive Testing
![Page 43: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/43.jpg)
Prevention V Guidelines
Used a score >80 by EBT to implement aggressive drug treatment in Framingham intermediate risk patients
In patients with a zero score, “one would not be justified to intervene with costly lipid lowering drugs at this time”
![Page 44: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/44.jpg)
Percent Volume Change vs LDL
+120%
0
–80%
60 120 200
LDL (mg/dL)
Treated Untreated Suboptimal Therapy (LDL >120 mg/dl)
Callister et al. N Engl J Med. 1998;339:1972-1978.
CA
C S
core
Ch
a ng
e
![Page 45: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/45.jpg)
-40
-20
0
20
40
60
80
100%
An
nu
ali
ze
d C
ha
ng
e
EBT 1 - EBT 2 EBT 2 - EBT 3
Achenbach S, Circulation, Vol 106: Aug. 27, 2002
Rates of Progression of CAC
25%
8.8%
P<0.0001
n=66
Before Statin After Statin
![Page 46: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/46.jpg)
-40
-20
0
20
40
60
80
100%
An
nu
ali
ze
d C
ha
ng
e
EBT 1 - EBT 2 EBT 2 - EBT 3
Achenbach S, Circulation, Vol 106: Aug. 27, 2002
32 Patients who achieved LDL <100 Mg/dL
27%
-3.4%
P=0.0001
n=32
Before Statin After Statin
![Page 47: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/47.jpg)
Annual Event Rate with Progression
01.5
6.45
0
1
2
3
4
5
6
7
Ann
ual E
vent
Rat
es
No progression 1-20% Increase >20% Increase
Annual CAC Score Change Raggi, Budoff AJC 2003
13X Risk
![Page 48: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/48.jpg)
Progression and Medical Intervention
0
50
100
150
200
250
300
Baseline 12 months 24 months 36 Months
![Page 49: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/49.jpg)
COMPLIANCE
“Willpower lasts about two weeks….
And is usually soluble in alcohol”
Mark Twain/Sam Clemens
![Page 50: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/50.jpg)
~50% of patients discontinue lipid-lowering therapy within 1 year.
~75% of patients discontinue lipid-lowering therapy within 2 years.
Compliance and Lipid-Lowering TherapyCompliance and Lipid-Lowering Therapy
Roberts, Am. J. Cardiol. 78:1996:377-378.
![Page 51: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/51.jpg)
Coronary Artery Scanning
SEVERECALCIFICATION
![Page 52: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/52.jpg)
Percentage of individuals maintaining Statin therapy at 3.6 years according to various levels of baseline CAC
No CAC CAC 1-99 CAC 100-399 CAC>4000
10
20
30
40
50
60
70
80
90
100
44
63
75
90
![Page 53: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/53.jpg)
Odds ratio of maintaining statin therapy with various levels of baseline CAC
2nd Quartile 3rd Quartile 4th Quartile0
5
10
15
20
25
30
2.4
5.1
1.1
4.2
1.9
9.19.3
3.0
28.9
![Page 54: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/54.jpg)
5 USES OF EBT
Use a calcium score to screen patients with moderate (intermediate) Framingham risk Positive EBT scans indicate incremental risk Alters therapeutic goal (LDL, BP, etc)
Identify patients who do not need further cardiac evaluation (scores of zero)
Consider serial imaging as ongoing management tool (progression)
Improve compliance Non-invasive Angiography
![Page 55: Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.](https://reader036.fdocuments.us/reader036/viewer/2022062421/56649d965503460f94a7f458/html5/thumbnails/55.jpg)
EBT Coronary Calcium